The Prostate Cancer Registry was the first and largest prospective, international, observational study of patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice.

These data extend the findings from randomized clinical trials, which include patients meeting well-defined inclusion and exclusion criteria.

Real-world data from this registry confirm the efficacy and safety of first- and second-line abiraterone acetate in patients with mCRPC, including a subset who had cardiovascular comorbidities.